GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Merck Tbk PT MERK.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

3,450

-1.15%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Merck Tbk PT

Its shares trade on IDX under the ticker MERK.JK. It has been listed since 23 July 1981. In the fiscal year to 31 December 2025, it reported revenue of IDR 1.20trn and net income of IDR 243.90bn. At that date it held total assets of IDR 1.27trn and shareholders' equity of IDR 975.71bn.

PT Merck Tbk engages in the pharmaceutical and chemical businesses. The company is headquartered in Jakarta Timur, Dki Jakarta. The firm delivers personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. The firm operates through three segments: Biopharma (ethical products), Consumer Health (over-the-counter products) and Others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
23 Jul 1981
Employees
376

Leadership

Pay as last reported

  • Ms. Mei Ling TangPresident Commissioner
  • Ms. Evie YulinPresident Director, Biopharma Director
  • Mr. Bambang NurcahyoFinance Director
  • Mr. Arryo Aritrixso Teguh Putranto WachjuwidajatPlant Director
  • Mrs. Melisa SandriantiCorporate Secretary
  • Mr. Parulian SimanjuntakIndependent Commissioner

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Jakarta Timur, Dki Jakarta, with 376 employees.
  • Operates through three segments: Biopharma, Consumer Health, and Others.
  • Provides personalized treatments for serious diseases and enables fertility solutions.

Weaknesses

  • No specific financial metrics provided for performance evaluation.
  • Limited information on market share or competitive positioning.
  • No details on product portfolio or R&D investment.

Opportunities

  • Expanding pharmaceutical and chemical businesses in Indonesia.
  • Growing demand for personalized treatments and fertility solutions.
  • Potential for segment expansion within Biopharma and Consumer Health.

Threats

  • Untrusted source description may contain inaccurate information.
  • Lack of transparency on financial data and operational details.
  • Competition in the pharmaceutical sector without specified market dynamics.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.